Status:
UNKNOWN
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors
Lead Sponsor:
Assiut University
Conditions:
Chemotherapy Effect
Eligibility:
All Genders
30-50 years
Brief Summary
Early detection of cardiomyopathy in patients receiving Anthracycline chemotherapy and determine if speckle tracking echo and Troponin gene will add benefit for early detection of cardiomyopathy. Imp...
Detailed Description
Anthracycline chemotherapy has saved the lives of many cancer victims during the 50 years after their discovery.These patients are prone to higher risk of cardiovascular death than the risk of tumor r...
Eligibility Criteria
Inclusion
- all Newly diagnosed cancer patients with who will receive Anthracycline based regimen chemotherapy
Exclusion
- Insufficient ultrasound image quality, defined as more than three LV segments being suboptimally visualized by conventional echocardiography.
- Valvular heart disease
- Hypertensive heart disease
- Cardiomyopathy
- Chronic renal failure
- Chronic obstructive air way disease (COPD)
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03381014
Start Date
January 1 2018
End Date
August 1 2019
Last Update
December 21 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.